Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have earned an average rating of “Hold” from the ten ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $30.00.
Several research firms recently weighed in on VYGR. Zacks Investment Research lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 21st. TheStreet downgraded Voyager Therapeutics from a “c-” rating to a “d+” rating in a research report on Friday, April 21st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $33.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, June 27th. BidaskClub raised Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Voyager Therapeutics in a research report on Wednesday, May 10th.
Several institutional investors have recently modified their holdings of the stock. Fiduciary Trust Co. raised its position in shares of Voyager Therapeutics by 19.1% in the first quarter. Fiduciary Trust Co. now owns 108,561 shares of the company’s stock valued at $1,437,000 after buying an additional 17,386 shares during the period. Schwab Charles Investment Management Inc. raised its position in shares of Voyager Therapeutics by 3.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 28,921 shares of the company’s stock valued at $383,000 after buying an additional 1,026 shares during the period. Wellington Management Group LLP raised its position in shares of Voyager Therapeutics by 17.4% in the first quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock valued at $1,739,000 after buying an additional 19,450 shares during the period. Bank of New York Mellon Corp raised its position in shares of Voyager Therapeutics by 15.6% in the first quarter. Bank of New York Mellon Corp now owns 44,018 shares of the company’s stock valued at $582,000 after buying an additional 5,952 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of Voyager Therapeutics by 114.4% in the first quarter. Wells Fargo & Company MN now owns 83,577 shares of the company’s stock valued at $1,107,000 after buying an additional 44,599 shares during the period. 41.19% of the stock is currently owned by institutional investors and hedge funds.
Shares of Voyager Therapeutics (NASDAQ VYGR) traded down 3.82% during midday trading on Tuesday, reaching $9.31. 26,851 shares of the company were exchanged. The company’s market capitalization is $249.99 million. Voyager Therapeutics has a 52-week low of $8.36 and a 52-week high of $18.25. The firm’s 50 day moving average is $9.37 and its 200-day moving average is $11.34.
Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, May 9th. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by $0.11. The business had revenue of $1.46 million for the quarter, compared to analysts’ expectations of $3.70 million. Voyager Therapeutics had a negative net margin of 457.45% and a negative return on equity of 35.25%. On average, equities analysts forecast that Voyager Therapeutics will post ($2.53) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://stocknewstimes.com/2017/07/18/voyager-therapeutics-inc-nasdaqvygr-given-average-rating-of-hold-by-analysts.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
